MetaCap

XTL Biopharmaceuticals Ltd. ADR (XTLB)

NASDAQ: XTLBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.37-0.085 (-5.84%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XTLB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.36
52-week range
1.37 – 5.64
Day range
1.37 – 1.59
Volume / Avg
1.78K / 6.58K
Beta
—

52-week range

$1.37$5.64

XTLB stock today

Shares of XTL Biopharmaceuticals (XTLB) finished lower on Nov 20 at $1.37, a drop of 5.84% or $0.085 per share, versus the S&P 500's 3.70% decline. Trading was light, with 1.78K shares changing hands, about 27% of the average daily volume. At this level, XTLB sits near the bottom of its 52-week range of $1.37 to $5.64: 75.7% below the high and 0.0% above the low.

XTL Biopharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.36), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About XTL Biopharmaceuticals

Company profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Noam Band
Headquarters
Herzliya, NY
Employees
4
Website
xtlbio.com

Financial highlights

Full financials

In fiscal 2024, XTL Biopharmaceuticals generated $451,000 in revenue. XTL Biopharmaceuticals reported a net loss of $1.0 million, compared with a loss of $1.8 million a year earlier. Gross margin was 0.7% and operating margin -481.6%.

XTL Biopharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$451.00K————
Growth—————
Net income$-1.03M$-1.78M$-1.35M$435.00K$-2.95M
EPS (diluted)$-0.003$-0.003$-0.002$0.00$-0.006

XTLB news

All XTLB news

XTL Biopharmaceuticals peers

Health Care sector
XTLB peer companies
CompanyPrice% ChgMarket capCompare
XBIOXenetic Biosciences Inc.1.40-9.09%$3.28Mvs XTLB
IMNNImunon Inc.0.5355-5.22%$3.47Mvs XTLB
APREAprea Therapeutics Inc.0.229-53.56%$3.25Mvs XTLB
NRSNNeuroSense Therapeutics Ltd.1.28+1.59%$3.19Mvs XTLB
KPRXKiora Pharmaceuticals Inc.0.7202-12.28%$3.19Mvs XTLB
MDCXMedicus Pharma Ltd.1.14-2.16%$3.16Mvs XTLB
AZTRAzitra Inc0.5168-2.75%$3.13Mvs XTLB
NCNANuCana plc ADR0.7495+4.39%$3.61Mvs XTLB

Indexes, lists and sector

XTL Biopharmaceuticals stock FAQ

What is XTL Biopharmaceuticals's stock price today?

XTLB last traded at $1.37 as of Nov 20, 4:00 PM EST, down 5.84% on the day. Prices are delayed at least 15 minutes.

Who is XTL Biopharmaceuticals's CEO?

Mr. Noam Band is the chief executive officer of XTL Biopharmaceuticals Ltd. ADR, which has about 4 employees.

What is the XTLB 52-week high?

The 52-week high for XTLB is $5.64 and the 52-week low is $1.37. The stock is currently 75.7% below its high.

Compare XTLB